Its role in sorafenib uptake has prompted us and other groups to investigate the usefulness of determining OCT1 expression in tumor tissue as a prognostic biomarker for the response to systemic treatment of HCC with this drug [13, 14, 17]. This evidence concerns the gene SLC22A1 and hepatocellular carcinoma.